RLAY vs. IBRX, ARWR, HCM, EWTX, MIRM, AMRX, KYMR, GMTX, PTGX, and MESO
Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include ImmunityBio (IBRX), Arrowhead Pharmaceuticals (ARWR), HUTCHMED (HCM), Edgewise Therapeutics (EWTX), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), Kymera Therapeutics (KYMR), Gemini Therapeutics (GMTX), Protagonist Therapeutics (PTGX), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry.
Relay Therapeutics vs.
ImmunityBio (NASDAQ:IBRX) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations.
In the previous week, ImmunityBio had 4 more articles in the media than Relay Therapeutics. MarketBeat recorded 9 mentions for ImmunityBio and 5 mentions for Relay Therapeutics. ImmunityBio's average media sentiment score of 0.20 beat Relay Therapeutics' score of 0.17 indicating that ImmunityBio is being referred to more favorably in the media.
ImmunityBio currently has a consensus target price of $13.58, indicating a potential upside of 273.17%. Relay Therapeutics has a consensus target price of $20.50, indicating a potential upside of 401.22%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than ImmunityBio.
Relay Therapeutics received 48 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 69.41% of users gave Relay Therapeutics an outperform vote while only 34.38% of users gave ImmunityBio an outperform vote.
Relay Therapeutics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 83.4% of ImmunityBio shares are owned by company insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
ImmunityBio has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
Relay Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Relay Therapeutics' return on equity.
Summary
Relay Therapeutics beats ImmunityBio on 11 of the 19 factors compared between the two stocks.
Get Relay Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relay Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RLAY) was last updated on 2/21/2025 by MarketBeat.com Staff
Free RLAY Stock Alerts